UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-08, Vol.330 (6), p.512

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

JAMA neurology, 2022-12, Vol.79 (12), p.1250

2022

Link zum Volltext

Verfügbarkeit prüfen

TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment

Alzheimer's & dementia, 2021-12, Vol.17 (S9), p.n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition

Alzheimer's research & therapy, 2021-01, Vol.13 (1), p.12-12, Article 12

2021

Link zum Volltext

Verfügbarkeit prüfen

The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population

Journal of Alzheimer's disease, 2019-01, Vol.67 (4), p.1181

2019

Link zum Volltext

Verfügbarkeit prüfen

TRAILBLAZER‐ALZ 3 – A Deeper Dive into Time‐to‐Event Trials

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

Pugh, Melissa A M

2023

Link zum Volltext

Verfügbarkeit prüfen

1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

Age and ageing, 2024-01, Vol.53 (Supplement_1)

2024

Link zum Volltext

Verfügbarkeit prüfen

TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months

Alzheimer's & dementia, 2023-12, Vol.19 (S24)

2023

Link zum Volltext

Verfügbarkeit prüfen

Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial

Alzheimer's & dementia, 2023-12, Vol.19 (S24)

2023

Link zum Volltext

Verfügbarkeit prüfen

Alz-Disc: A Tool to Discriminate Disease-causing and Neutral Mutations in Alzheimer's Disease

Combinatorial chemistry & high throughput screening, 2023-01, Vol.26 (4), p.769

2023

Link zum Volltext

Verfügbarkeit prüfen

Alzheimer's Association launches ALZ‐NET: A long‐term data collection and sharing network for new treatments

Alzheimer's & dementia, 2022-09, Vol.18 (9), p.1694-1695

2022

Link zum Volltext

Verfügbarkeit prüfen

Consensus meta‐analysis of genome‐wide association studies for Alzheimer’s disease across the EADB, PGC‐ALZ and IGAP consortia

Alzheimer's & dementia, 2023-12, Vol.19 (S12)

Bellenguez, Céline

2023

Link zum Volltext

Verfügbarkeit prüfen

‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

The journal of prevention of Alzheimer's disease, 2023, Vol.10 (3), p.595-599

2023

Link zum Volltext

Verfügbarkeit prüfen

Reasons for study exclusion by sex in lanabecestat studies AMARANTH and DAYBREAK‐ALZ: Human/Human trials: Other

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Link zum Volltext

Verfügbarkeit prüfen

Retraction: Wang, K, Tang, W, Hao, X, Zhao, J. Ultra‐processed food consumption and risk of dementia and Alzheimer's disease: Long‐term results from the Framingham Offspring Study. Alzheimer's Dement. 2023; 1–11. https://doi.org/10.1002/alz.13351

Alzheimer's & dementia, 2023-12, Vol.19 (12), p.5988-5988

2023

Link zum Volltext

Verfügbarkeit prüfen

Use of plasma P‐tau217 for enrichment in the Phase 2 PROSPECT‐ALZ study of LY3372689 in early symptomatic Alzheimer’s disease: Cohort selection and baseline characteristics

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

ALZ i-Connect: A Novel Audiovisual Care Consultation for Caregivers

American journal of Alzheimer's disease and other dementias, 2017-02, Vol.32 (1), p.63-66

2017

Link zum Volltext

Verfügbarkeit prüfen

CAD-ALZ: A Blockwise Fine-Tuning Strategy on Convolutional Model and Random Forest Classifier for Recognition of Multistage Alzheimer's Disease

Diagnostics (Basel), 2023-01, Vol.13 (1), p.167

2023

Link zum Volltext

Verfügbarkeit prüfen

The clinical use of blood-test factors for Alzheimer’s disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit

Experimental and Molecular Medicine, 2021, 53(0), , pp.1-9

2021

Link zum Volltext

Verfügbarkeit prüfen

Reasons for study exclusion by sex in lanabecestat studies AMARANTH and DAYBREAK‐ALZ

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel use of tau imaging to enrich for pathological homogeneity within the PERISCOPE‐ALZ study of zagotenemab

Alzheimer's & dementia, 2021-12, Vol.17 (S9), p.n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Alz-SAENet: A Deep Sparse Autoencoder based Model for Alzheimer’s Classification

International journal of advanced computer science & applications, 2022, Vol.13 (10)

2022

Link zum Volltext

Verfügbarkeit prüfen

ALZ i-Connect

American journal of Alzheimer's disease and other dementias, 2017-02, Vol.32 (1), p.63-66

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106.953

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51.512)
Mit Volltextzugriff
(62.450)

Publikationsform

10 weitere anzeigen...

Weniger anzeigen...

Sprache

Niederländisch
(60.515)
Englisch
(45.220)
Spanisch
(1.596)
Deutsch
(1.422)
Japanisch
(1.368)
Italienisch
(1.054)
Portugiesisch
(387)
Französisch
(282)
Latein
(47)
Norwegisch
(27)
Chinesisch
(24)
Afrikaans
(13)
Russisch
(7)
Katalanisch
(5)
Ndonga
(4)
Türkisch
(4)
Arabisch
(3)
Tschechisch
(3)
Polnisch
(3)
Slowakisch
(3)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Medicine & Public Health
(24.653)
Medicine
(23.717)
Science & Technology
(12.367)
Life Sciences & Biomedicine
(9.905)
Humans
(7.804)
Psychology
(7.046)
Primary Care Medicine
(5.893)
Neurosciences & Neurology
(5.829)
Nursing
(5.491)
Alzheimer's Disease
(5.312)
Social Sciences
(4.549)
Clinical Neurology
(4.491)
Behavioral Science And Psychology
(3.835)
Health Care Management
(3.834)
Dementia
(3.582)
Business And Management
(3.388)
Aged
(3.188)
Female
(3.146)
Male
(3.114)
Neurosciences
(2.989)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(30.445)
Springer Nature
(29.680)
Journals@Ovid Complete
(26.543)
Wiley HSS Collection
(25.813)
Elsevier ScienceDirect Journals Complete
(21.619)
Electronic Journals Library
(14.340)
JSTOR
(6.077)
IngentaConnect Journals
(5.886)
Brill Online Journals
(4.194)
NUS Single-Journal Subscriptions
(3.397)
Wiley Online Library Full Collection 2018
(3.163)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.185)
Factiva
(2.058)
2022 Brill Journal Collection
(1.591)
Amsterdam University Press Tijdschriften
(1.357)
Nexis Uni
(1.324)
Nature Journals Online
(1.293)
Ebook Central Perpetual and DDA
(1.136)
eBooks on EBSCOhost
(1.101)
SAGE Complete
(761)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Alzheimer's & Dementia
(20.869)
Huisarts En Wetenschap
(4.108)
Tijdschrift Voor Bedrijfs- En Verzekeringsgeneeskunde
(2.627)
Tandartspraktijk
(2.436)
Alzheimer Disease And Associated Disorders
(1.773)
Nederlandsch Archief Voor Kerkgeschiedenis
(1.694)
Skipr
(1.573)
Tsg : Tijdschrift Voor Gezondheidswetenschappen
(1.570)
Podopost
(1.466)
Het Vogeljaar
(1.465)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment

Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition

The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population

TRAILBLAZER‐ALZ 3 – A Deeper Dive into Time‐to‐Event Trials

1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer’s Treatment and Care

TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months

Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial

Alz-Disc: A Tool to Discriminate Disease-causing and Neutral Mutations in Alzheimer's Disease

Alzheimer's Association launches ALZ‐NET: A long‐term data collection and sharing network for new treatments

Consensus meta‐analysis of genome‐wide association studies for Alzheimer’s disease across the EADB, PGC‐ALZ and IGAP consortia

‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

Reasons for study exclusion by sex in lanabecestat studies AMARANTH and DAYBREAK‐ALZ: Human/Human trials: Other

Retraction: Wang, K, Tang, W, Hao, X, Zhao, J. Ultra‐processed food consumption and risk of dementia and Alzheimer's disease: Long‐term results from the Framingham Offspring Study. Alzheimer's Dement. 2023; 1–11. https://doi.org/10.1002/alz.13351

Use of plasma P‐tau217 for enrichment in the Phase 2 PROSPECT‐ALZ study of LY3372689 in early symptomatic Alzheimer’s disease: Cohort selection and baseline characteristics

ALZ i-Connect: A Novel Audiovisual Care Consultation for Caregivers

CAD-ALZ: A Blockwise Fine-Tuning Strategy on Convolutional Model and Random Forest Classifier for Recognition of Multistage Alzheimer's Disease

The clinical use of blood-test factors for Alzheimer’s disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit

Reasons for study exclusion by sex in lanabecestat studies AMARANTH and DAYBREAK‐ALZ

Novel use of tau imaging to enrich for pathological homogeneity within the PERISCOPE‐ALZ study of zagotenemab

Alz-SAENet: A Deep Sparse Autoencoder based Model for Alzheimer’s Classification

ALZ i-Connect

Suchergebnisse filtern